Toxins (Oct 2022)

AbobotulinumtoxinA Doses in Upper and Lower Limb Spasticity: A Systematic Literature Review

  • Alexis Schnitzler,
  • Clément Dince,
  • Andreas Freitag,
  • Ike Iheanacho,
  • Kyle Fahrbach,
  • Louis Lavoie,
  • Jean-Yves Loze,
  • Anne Forestier,
  • David Gasq

DOI
https://doi.org/10.3390/toxins14110734
Journal volume & issue
Vol. 14, no. 11
p. 734

Abstract

Read online

Disabling limb spasticity can result from stroke, traumatic brain injury or other disorders causing upper motor neuron lesions such as multiple sclerosis. Clinical studies have shown that abobotulinumtoxinA (AboBoNT-A) therapy reduces upper and lower limb spasticity in adults. However, physicians may administer potentially inadequate doses, given the lack of consensus on adjusting dose according to muscle volume, the wide dose ranges in the summary of product characteristics or cited in the published literature, and/or the high quantity of toxin available for injection. Against this background, a systematic literature review based on searches of MEDLINE and Embase (via Ovid SP) and three relevant conferences (2018 to 2020) was conducted in November 2020 to examine AboBoNT-A doses given to adults for upper or lower limb muscles affected by spasticity of any etiology in clinical and real-world evidence studies. From the 1781 unique records identified from the electronic databases and conference proceedings screened, 49 unique studies represented across 56 publications (53 full-text articles, 3 conference abstracts) were eligible for inclusion. Evidence from these studies suggested that AboBoNT-A dose given per muscle in clinical practice varies considerably, with only a slight trend toward a relationship between dose and muscle volume. Expert-based consensus is needed to inform recommendations for standardizing AboBoNT-A treatment initiation doses based on muscle volume.

Keywords